UTIs therapeutics currently exhibits a proliferating pipeline with 40 drug candidates, according to P&S Market Research
Urinary tract infection (UTI) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Clinically, UTIs are categorized as uncomplicated and complicated. Uncomplicated UTIs typically occur in a healthy adult non-pregnant woman and have no structural or neurological urinary tract abnormalities; these infections are differentiated into cystitis and pyelonephritis.
UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. Gram-negative rod Escherichia coli is the most common cause of UTIs in all settings and is transmitted by person-to-person direct contact and the fecal-oral route. The study analyzed that UTIs therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.
According to the research findings, a majority of the drug candidates for the treatment of UTIs are being developed as small molecules. It has been observed that the drugs that are being developed as small molecules are easy to manufacture with high production rate.
Browse Detailed Report on "Urinary Tract Infections (UTIs) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline
Significant growth due to various technological advancements
It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature. The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.
The pipeline has more drug candidates being developed as combination therapies
The companies involved in the UTIs therapeutic pipeline are developing various drug candidates as combination therapies, that have several advantages such as, improved medication compliance by decreasing the pill burden of patients, increased efficacy, and reduced side effects and cost. For instance, C-Scape, a Phase I drug candidate by Achaogen Inc. is a combination of ceftibuten and clavulanate, that are small molecules obtained from the synthetic source. Both ceftibuten and clavulanate act by different mechanism of action but give synergistic effects. Ceftibuten acts as cell wall synthesis inhibitor and, clavulanate acts as beta-lactamase inhibitor.
Some of the key players involved in the development of UTIs therapeutics pipeline include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.
UTIs Therapeutics Pipeline Analysis